$ADVM News
Last published 11mo ago
- 11mo agoLLYADVMLilly and Adverum announce expiration and completion of Adverum tender offer and acquisitionPR NewswireEli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying...
- 11mo agoADVMAdverum Reminds Stockholders to Tender their Shares into the Offer by LillyGlobeNewswireREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to
- 1y agoLLYADVMLilly to Acquire Adverum BiotechnologiesPR NewswireEli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene...
- 1y agoADVMAdverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular DegenerationGlobeNewswireScreening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE)
- 1y agoADVMAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting
- 1y agoADVMCLNNCUAUFDERM+27Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth
- 1y agoADVMAdverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline HighlightsGlobeNewswire- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in
- 1y agoADVMAdverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceGlobeNewswireREDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished
- 1y agoADVMAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting
- 1y agoADVMAdverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline HighlightsGlobeNewswire- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level
- 1y agoADVMAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of
- 1y agoADVMAdverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated MilestonesGlobeNewswireREDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular
- 1y agoADVMAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award
- 1y agoADVMAdverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual ConferenceGlobeNewswireREDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 1y agoADVMAdverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMDGlobeNewswireIxo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS is the first-ever
- 1y agoADVMAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting
- 1y agoADVMAdverum Biotechnologies to Participate in the Cowen 45th Annual Health Care ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 1y agoADVMAdverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 1y agoADVMAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that on December 4, 2024, the Compensation Committee of Adverum's Board of Directors granted
- 1y agoADVMAdverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an
- 1y agoADVMAdverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design ElementsGlobeNewswire- 52-week LUNA data combined with follow-up from OPTIC at 4 years continue to support long-term potential best-in-class product profile of Ixo-vec - 6E10 dose in LUNA maintains visual and anatomic
- 1y agoADVMAdverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design ElementsGlobeNewswire– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc.
- 2y agoADVMAdverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated MilestonesGlobeNewswire- 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2
- 2y agoADVMAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal ProgramGlobeNewswireREDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today
- 2y agoADVMAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverum's Board of Directors granted
- 2y agoADVMAdverum Biotechnologies to Participate in Upcoming Fall Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate HighlightsGlobeNewswire- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable
- 2y agoADVMAdverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceGlobeNewswireREDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMDGlobeNewswireREDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update TranscriptEarnings Call Transcripts
- 2y agoADVMAdverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual MeetingGlobeNewswire- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were
- 2y agoADVMAdverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual MeetingGlobeNewswireREDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA SummitGlobeNewswireREDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsGlobeNewswire- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations
- 2y agoADVMAdverum Biotechnologies to Participate in Upcoming May Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingGlobeNewswireREDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesGlobeNewswire- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million
- 2y agoADVMAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDGlobeNewswire– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
- 2y agoADVMAdverum Biotechnologies Announces $127.5 Million Private Placement FinancingGlobeNewswire- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare Capital Partners and Vivo
- 2y agoADVMAdverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024GlobeNewswire- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on
- 2y agoADVMAdverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerGlobeNewswireREDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula SocietyGlobeNewswireREDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular
- 2y agoADVMAdverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular
- 3y agoADVMAdverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline HighlightsGlobeNewswire- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC
- 3y agoADVMAdverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular
- 3y agoADVMAdverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023GlobeNewswire- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF
- 3y agoACHLADVMAVIRBOLT+610 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical
- 3y agoADVMAdverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 TrialGlobeNewswire- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range - - Ixo-vec has been well tolerated with a